Introduction: Preeclampsia (PE) is a disease that continues to be the main cause of maternal and fetal mortality and complications in 5-8% of pregnancies characterized by hypertension and proteinuria and is one of the leading causes of maternal and perinatal mortality. Our group recently demonstrated that PIGF genetic polymorphisms affect the susceptibility to preeclampsia (PE). Objective: To improve the prognosis and early diagnosis of preeclampsia based on clinical-genetic and endothelial predictors for rational management of patients with preeclampsia, reducing maternal and perinatal mortality. Methods: We examined 160 pregnant women aged 18 to 40 years with a physiological course of pregnancy observed in the 2,3 __ampersandsignndash;maternity complexes of Samarkand (11-40 weeks). The concentration of PIGF and sFlt-1 in the blood serum of pregnant women was determined. Total genomic DNA was isolated, single-nucleoid polymorphisms were detected by real-time polymerase chain. Results: In patients with preeclampsia, the concentration of PIGF, sFlt-1, and their ratio values significantly differed from those in patients with the physiological course of pregnancy, and the dependence of the detected changes on the severity of preeclampsia was also observed. Conclusion: Concentrations of PIGF, sFlt-1 and their ratio values are highly informative indicators of preeclampsia. Their ratio should be carried out in the first and second trimesters of pregnancy as part of screening programs. The determination of preeclampsia markers at the end of the second and third trimester of pregnancy can serve as a basis for the final diagnosis of preeclampsia and the development of tactics for prolonging pregnancy